A number of receptors with relevance in many cancers, can increase the NAS/melatonin ratio either by melatonin metabolism and/or via the ‘backward’ conversion of melatonin to NAS via O-demethylation, including the aryl hydrocarbon receptor (AhR), purinergic P2Y1 receptor, and the metabotropic glutamate receptor (mGluR)5 [10]. This evidence concerns the gene AHR and cancer.